09/14/2020 | 02:43am EDT
|
long trade  On stand-by |
|
Entry price : 87.54€ | Target : 94€ | Stop-loss : 83€ | Potential : 7.38% |
| From a horizontal accumulation phase, the timing seems good to buy shares in Sanofi and to get ahead of a break-out on the upside of the congestion area. Investors have an opportunity to buy the stock and target the € 94. |
 |
Summary
- The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
- The company has solid fundamentals for a short-term investment strategy.
- Sanofi accounts for 4.55 % of our European Portfolio. A trade is currently open since 06/10/2020 with a purchase price of € 90.28. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 9.56 and 17.86 for the ongoing fiscal year and 2021 respectively, makes the stock pretty attractive with regard to earnings multiples.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Within the weekly time frame the stock shows a bullish technical configuration above the support level at 83.56 EUR
Weaknesses
- The company’s earnings releases usually do not meet expectations.
|
|
|||||||||||||||
|
|||||||||||||||
Disclaimer:
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor’s sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.
|
|
Income Statement Evolution
Consensus
|
Sell |
|
Buy |
| Mean consensus | BUY |
| Number of Analysts | 25 |
| Average target price | 105,58 € |
| Last Close Price | 87,54 € |
| Spread / Highest target | 40,3% |
| Spread / Average Target | 20,6% |
| Spread / Lowest Target | -2,90% |
